Previous 10 | Next 10 |
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to...
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022. Ron Rocca, Exagen’s President...
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2 Conference, which takes place May 3 rd - 4 th , 2022, in New York City at...
Exagen (NASDAQ:XGN) announced an in-network deal with Evolutions Healthcare Systems offering access to AVISE tests to participating members. The deal includes XGN's AVISE Lupus and AVISE CTD tests, making AVISE diagnostic testing available as an in-network benefit. For further details ...
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to part...
The following slide deck was published by Exagen Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Exagen Inc. 2021 Q4 - Results - Earnings Call Presentation
Exagen (NASDAQ:XGN) disclosed in its annual report that it has received a subpoena from the U.S. Department of Justice "requesting documents related to its investigation of potential federal regulatory healthcare offenses." The company said that it is cooperating fully and is working to provi...
Image source: The Motley Fool. Exagen Inc. (NASDAQ: XGN) Q4 2021 Earnings Call Mar 22, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Exagen Inc. (XGN) Q4 2021 Earnings Call Transcript
Exagen Inc. (XGN) Q4 2021 Earnings Conference Call March 22, 2022 4:30 PM ET Company Participants Ryan Douglas - Investor Relations Ron Rocca - President and Chief Executive Officer Kamal Adawi - Chief Financial Officer Mark Hazeltine - COO Conference Call Participants Kyle Mikson - Canaccord...
Exagen press release (NASDAQ:XGN): Q4 GAAP EPS of -$0.42 beats by $0.04. Revenue of $12.69M (+0.2% Y/Y) beats by $0.97M. For further details see: Exagen GAAP EPS of -$0.42 beats by $0.04, revenue of $12.69M beats by $0.97M
News, Short Squeeze, Breakout and More Instantly...
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: Recognized total revenue of $14.4 million in the ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...
CARLSBAD, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2024, before the market opens on Monday, May 13, 2024. John Aballi, Exagen’s President and Chief Executiv...